Table 1 Baseline demographic and clinical characteristics of patients with UC initiating tofacitinib, vedolizumab or a TNFi
Demographics | Tofacitinib (N = 225) | Vedolizumab (N = 373) | TNFi (N = 940) |
|---|---|---|---|
Duration of variable-length baseline period (years), mean (SD) | 3.4 (1.8) | 3.5 (1.8) | 3.5 (1.8) |
Age at index date (years), mean (SD) | 45.6 (16.5) | 48.7 (18.0) | 45.8 (17.1) |
Gender, n (%) | |||
 Female | 113 (50.2) | 188 (50.4) | 466 (49.6) |
 Male | 112 (49.8) | 185 (49.6) | 474 (50.4) |
Biologic treatment history, n (%) | |||
 Biologic-naïve | 43 (19.1) | 307 (82.3) | 881 (93.7) |
 1 prior biologic | 92 (40.9) | 49 (13.1) | 49 (5.2) |
 ≥ 2 prior biologics | 90 (40.0) | 17 (4.6) | 10 (1.1) |
Oral corticosteroid use, n (%)a | 173 (76.9) | 254 (68.1) | 693 (73.7) |
Geographic region, n (%) | |||
 Northeast | 26 (11.6) | 46 (12.3) | 102 (10.9) |
 Midwest | 49 (21.8) | 108 (29.0) | 263 (28.0) |
 South | 97 (43.1) | 162 (43.4) | 427 (45.4) |
 West | 53 (23.6) | 57 (15.3) | 148 (15.7) |
12-month baseline Quan-Charlson comorbidity score, mean (SD) | 0.7 (1.3) | 0.8 (1.5) | 0.8 (1.3) |
12-month baseline Quan-Charlson comorbidity score, n (%) | |||
 0 | 152 (67.6) | 233 (62.5) | 602 (64.0) |
 1 | 34 (15.1) | 57 (15.3) | 154 (16.4) |
 2 | 23 (10.2) | 48 (12.9) | 97 (10.3) |
 3 | 8 (3.6) | 13 (3.5) | 45 (4.8) |
 4 | 3 (1.3) | 9 (2.4) | 22 (2.3) |
 ≥ 5 | 5 (2.2) | 13 (3.5) | 20 (2.1) |